CureGenetics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 57

Employees

  • Latest Deal Type
  • Series B2

  • Latest Deal Amount
  • $9M

  • Investors
  • 7

CureGenetics General Information

Description

Developer of cell and gene therapy platforms designed to develop treatments for solid tumors and genetic diseases. The company's platforms offer CAR-NKT cell therapy development and AAV vector screening capabilities for targeted gene delivery and tumor treatment, enabling biotechnology and pharmaceutical companies to develop novel therapies for difficult-to-treat diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Buildings B20 (1st-2nd floors) and C29 (Phase II) of the Biomedical Industrial Park
  • Number 218 Sangtian Street
  • Suzhou, Jiangsu 215000
  • China
+86 180
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Corporate Office
  • Buildings B20 (1st-2nd floors) and C29 (Phase II) of the Biomedical Industrial Park
  • Number 218 Sangtian Street
  • Suzhou, Jiangsu 215000
  • China
+86 180

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CureGenetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B2) 28-Mar-2024 $9M Completed Generating Revenue
8. Secondary Transaction - Private 20-Oct-2022 Completed Generating Revenue
7. Later Stage VC (Series B) 01-Dec-2021 Completed Generating Revenue
6. Early Stage VC 12-Jan-2021 Completed Generating Revenue
5. Early Stage VC (Series A2) 23-Nov-2020 Completed Generating Revenue
4. Early Stage VC (Series A1) 19-Mar-2020 Completed Generating Revenue
3. Secondary Transaction - Private 09-Nov-2018 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Mar-2018 $17M $19.1M Completed Generating Revenue
1. Seed Round 22-Dec-2016 $2.12M $2.12M Completed Startup
To view CureGenetics’s complete valuation and funding history, request access »

CureGenetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell and gene therapy platforms designed to develop treatments for solid tumors and genetic diseases. The c
Discovery Tools (Healthcare)
Suzhou, China
57 As of 2019

Hangzhou, China
 

Lebanon, NH
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CureGenetics Competitors (39)

One of CureGenetics’s 39 competitors is GMAX Bio, a Venture Capital-Backed company based in Hangzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GMAX Bio Venture Capital-Backed Hangzhou, China
Adimab Venture Capital-Backed Lebanon, NH
Mabworks Biotech Venture Capital-Backed Beijing, China
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 39 competitors. Get the full list »

CureGenetics Patents

CureGenetics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4460512-A1 Novel interleukin-2 polypeptides Pending 07-Jan-2022
EP-4460512-A4 Novel interleukin-2 polypeptides Pending 07-Jan-2022
US-20250163117-A1 Novel interleukin-2 polypeptides Pending 07-Jan-2022
WO-2023131270-A1 Novel interleukin-2 polypeptides Inactive 07-Jan-2022
EP-4386010-A1 Modified cell, and preparation method therefor and use thereof Pending 12-Aug-2021 A61K40/11
To view CureGenetics’s complete patent history, request access »

CureGenetics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CureGenetics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advantech Capital Partners PE/Buyout Minority
Blue Ocean Capital Group Venture Capital Minority
Ming Bioventures Venture Capital Minority
Suzhou Oriza Holdings Corporation Asset Manager Minority
Qiming Venture Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

CureGenetics FAQs

  • When was CureGenetics founded?

    CureGenetics was founded in 2016.

  • Where is CureGenetics headquartered?

    CureGenetics is headquartered in Suzhou, China.

  • What is the size of CureGenetics?

    CureGenetics has 57 total employees.

  • What industry is CureGenetics in?

    CureGenetics’s primary industry is Discovery Tools (Healthcare).

  • Is CureGenetics a private or public company?

    CureGenetics is a Private company.

  • What is CureGenetics’s current revenue?

    The current revenue for CureGenetics is .

  • How much funding has CureGenetics raised over time?

    CureGenetics has raised $125M.

  • Who are CureGenetics’s investors?

    Advantech Capital Partners, Blue Ocean Capital Group, Ming Bioventures, Suzhou Oriza Holdings Corporation, and Qiming Venture Partners are 5 of 7 investors who have invested in CureGenetics.

  • Who are CureGenetics’s competitors?

    GMAX Bio, Adimab, Mabworks Biotech, CytomX Therapeutics, and Xenetic Biosciences are some of the 39 competitors of CureGenetics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process